Loading...
•
Sep 30, 2022
TransMedics Q3 2022 Earnings Report
TransMedics' Q3 2022 financial performance showcased substantial revenue growth driven by strong demand for its OCS technology and NOP integrated offering, alongside a raised full-year revenue guidance.
Key Takeaways
TransMedics reported a significant increase in net revenue for Q3 2022, reaching $25.7 million, a 378% increase compared to Q3 2021. This growth was primarily driven by the adoption of the OCS technology and the National OCS Program (NOP). The company has updated its full-year 2022 revenue guidance to $80 million to $85 million.
Net revenue reached $25.7 million, a 378% increase compared to Q3 2021.
Revenue excluding a $1.4 million adjustment was $24.3 million, a 349% increase compared to Q3 2021.
Transplant centers' use of the National OCS Program (NOP) drove approximately 90% of total US revenue.
Completed public offering of common stock for approximately $140 million in net proceeds.
Forward Guidance
TransMedics is updating full year 2022 revenue to be in the range of $80 million to $85 million, excluding the $1.4 million favorable change in estimate for contra revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...